JPWO2020172621A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172621A5 JPWO2020172621A5 JP2021548675A JP2021548675A JPWO2020172621A5 JP WO2020172621 A5 JPWO2020172621 A5 JP WO2020172621A5 JP 2021548675 A JP2021548675 A JP 2021548675A JP 2021548675 A JP2021548675 A JP 2021548675A JP WO2020172621 A5 JPWO2020172621 A5 JP WO2020172621A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 13
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims 1
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000011363 radioimmunotherapy Methods 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024173444A JP2025016471A (ja) | 2019-02-22 | 2024-10-02 | Ｃｄ３３抗体とそれを用いた癌を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809091P | 2019-02-22 | 2019-02-22 | |
| US62/809,091 | 2019-02-22 | ||
| PCT/US2020/019351 WO2020172621A1 (en) | 2019-02-22 | 2020-02-21 | Cd33 antibodies and methods of using the same to treat cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024173444A Division JP2025016471A (ja) | 2019-02-22 | 2024-10-02 | Ｃｄ３３抗体とそれを用いた癌を治療する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523188A JP2022523188A (ja) | 2022-04-21 |
| JP2022523188A5 JP2022523188A5 (https=) | 2023-03-06 |
| JPWO2020172621A5 true JPWO2020172621A5 (https=) | 2023-03-06 |
| JP7598324B2 JP7598324B2 (ja) | 2024-12-11 |
Family
ID=72144738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548675A Active JP7598324B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３３抗体とそれを用いた癌を治療する方法 |
| JP2024173444A Pending JP2025016471A (ja) | 2019-02-22 | 2024-10-02 | Ｃｄ３３抗体とそれを用いた癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024173444A Pending JP2025016471A (ja) | 2019-02-22 | 2024-10-02 | Ｃｄ３３抗体とそれを用いた癌を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12441793B2 (https=) |
| EP (1) | EP3927749A4 (https=) |
| JP (2) | JP7598324B2 (https=) |
| KR (1) | KR20210142628A (https=) |
| CN (2) | CN120329441A (https=) |
| AU (1) | AU2020225631A1 (https=) |
| BR (1) | BR112021016398A2 (https=) |
| CA (1) | CA3131019A1 (https=) |
| CO (1) | CO2021011944A2 (https=) |
| MX (1) | MX2021009975A (https=) |
| WO (1) | WO2020172621A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| EP3636752A4 (en) | 2018-07-25 | 2021-04-28 | Alteogen, Inc. | NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| MY204342A (en) | 2019-03-25 | 2024-08-24 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| WO2021083467A1 (en) * | 2019-10-28 | 2021-05-06 | Y-Mabs Therapeutics, Inc. | Administration of cd22, cd33 and/or tim-3 antibodies using ommaya reservoirs for the treatment of cns cancer or neurodegenerative diseases |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| WO2021242848A1 (en) * | 2020-05-27 | 2021-12-02 | Memorial Sloan Kettering Cancer Center | Anti-gd2 sada conjugates and uses thereof |
| JP7622088B2 (ja) | 2020-08-07 | 2025-01-27 | アルテオジェン・インコーポレイテッド | 組換えヒアルロニダーゼの生産方法 |
| US20240415888A1 (en) * | 2021-10-20 | 2024-12-19 | Memorial Sloan Kettering Cancer Center | Anti-tshr multi-specific antibodies and uses thereof |
| EP4608871A1 (en) * | 2022-10-26 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | Cd33 antibody compositions for treating alzheimer's disease |
| AU2024283114A1 (en) * | 2023-06-01 | 2026-01-22 | Actinium Pharmaceuticals, Inc. | Combination therapies for the treatment of cd33-positive hematological malignancies harboring mutations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101210048A (zh) * | 2006-12-29 | 2008-07-02 | 中国医学科学院血液学研究所 | 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| JP7376977B2 (ja) | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| DK3380522T5 (da) | 2015-11-25 | 2024-09-30 | Visterra Inc | Antistofmolekyler til april og anvendelser deraf |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| KR20190140943A (ko) | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| KR102733407B1 (ko) | 2017-08-03 | 2024-11-21 | 알렉터 엘엘씨 | 항-cd33 항체 및 이의 이용 방법 |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
-
2020
- 2020-02-21 AU AU2020225631A patent/AU2020225631A1/en active Pending
- 2020-02-21 KR KR1020217029876A patent/KR20210142628A/ko active Pending
- 2020-02-21 US US17/432,265 patent/US12441793B2/en active Active
- 2020-02-21 JP JP2021548675A patent/JP7598324B2/ja active Active
- 2020-02-21 EP EP20758925.0A patent/EP3927749A4/en active Pending
- 2020-02-21 BR BR112021016398A patent/BR112021016398A2/pt unknown
- 2020-02-21 CN CN202411916396.4A patent/CN120329441A/zh active Pending
- 2020-02-21 MX MX2021009975A patent/MX2021009975A/es unknown
- 2020-02-21 CA CA3131019A patent/CA3131019A1/en active Pending
- 2020-02-21 WO PCT/US2020/019351 patent/WO2020172621A1/en not_active Ceased
- 2020-02-21 CN CN202080029923.3A patent/CN114502584B/zh active Active
-
2021
- 2021-09-13 CO CONC2021/0011944A patent/CO2021011944A2/es unknown
-
2024
- 2024-10-02 JP JP2024173444A patent/JP2025016471A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| ES2789573T3 (es) | Anticuerpos multiespecíficos con afinidad por el antígeno A33 humano y el complejo metálico de DOTA | |
| Kobayashi et al. | Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology | |
| JP2017512765A5 (https=) | ||
| JP2019513018A5 (https=) | ||
| WO2020102779A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| JP2013512920A5 (https=) | ||
| JPWO2020172621A5 (https=) | ||
| JP2006507803A5 (https=) | ||
| JP2006513695A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| TW202112354A (zh) | 遮蔽抗體調配物 | |
| US20150071950A1 (en) | C-met targeting compound-bioactive material conjugate and use thereof | |
| ES2971126T3 (es) | Anticuerpos contra LIF y usos de los mismos | |
| BR112020018560A2 (pt) | Agentes de ligação bi específicos e usos dos mesmos | |
| ES3053942T3 (en) | Anti-stem cell factor antibodies and methods of use thereof | |
| JP2021517816A5 (https=) | ||
| JP2020522512A5 (https=) | ||
| JP2025015580A (ja) | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 | |
| KR20230028386A (ko) | 인간 질환의 치료를 위한 cd38 항체 | |
| Burvenich et al. | Biodistribution and planar gamma camera imaging of 123I-and 131I-labeled F (ab′) 2 and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor | |
| Braga Ligiero et al. | Monoclonal antobodies: Application in radiopharmacy | |
| JPWO2020264211A5 (https=) | ||
| Chen et al. | Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy | |
| JPWO2020210232A5 (https=) |